NASDAQ:ANIP ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis $72.95 +2.26 (+3.20%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$72.96 +0.00 (+0.01%) As of 05/2/2025 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About ANI Pharmaceuticals Stock (NASDAQ:ANIP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ANI Pharmaceuticals alerts:Sign Up Key Stats Today's Range$70.06▼$73.1650-Day Range$54.58▼$72.9552-Week Range$52.50▼$73.16Volume322,989 shsAverage Volume282,723 shsMarket Capitalization$1.59 billionP/E RatioN/ADividend YieldN/APrice Target$80.13Consensus RatingBuy Company OverviewANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Read More… ANI Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScoreANIP MarketRank™: ANI Pharmaceuticals scored higher than 78% of companies evaluated by MarketBeat, and ranked 266th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingANI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageANI Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ANI Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth9.07% Earnings GrowthEarnings for ANI Pharmaceuticals are expected to grow by 9.07% in the coming year, from $3.86 to $4.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ANI Pharmaceuticals is -132.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ANI Pharmaceuticals is -132.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioANI Pharmaceuticals has a P/B Ratio of 3.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ANI Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted12.86% of the float of ANI Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in ANI Pharmaceuticals has recently decreased by 10.61%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldANI Pharmaceuticals does not currently pay a dividend.Dividend GrowthANI Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.3 / 5Environmental Score-2.48 Percentage of Shares Shorted12.86% of the float of ANI Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in ANI Pharmaceuticals has recently decreased by 10.61%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News Sentiment1.02 News SentimentANI Pharmaceuticals has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for ANI Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for ANIP on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $197,792.00 in company stock.Percentage Held by Insiders11.10% of the stock of ANI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.05% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ANI Pharmaceuticals' insider trading history. Receive ANIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIP Stock News HeadlinesAnalysts Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Target Price at $80.13May 4 at 1:07 AM | americanbankingnews.comGeneric Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The RestApril 28, 2025 | msn.comTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.May 4, 2025 | Porter & Company (Ad)ANI Pharmaceuticals (NASDAQ:ANIP) Lowered to Sell Rating by StockNews.comApril 24, 2025 | americanbankingnews.comANI Pharmaceuticals price target raised to $65 from $62 at TruistApril 22, 2025 | markets.businessinsider.comANI Pharmaceuticals (ANIP): Buy, Sell, or Hold Post Q4 Earnings?April 16, 2025 | uk.finance.yahoo.comGuggenheim Sticks to Its Buy Rating for ANI Pharmaceuticals (ANIP)April 12, 2025 | markets.businessinsider.comDeep Dive Into ANI Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)April 11, 2025 | benzinga.comSee More Headlines ANIP Stock Analysis - Frequently Asked Questions How have ANIP shares performed this year? ANI Pharmaceuticals' stock was trading at $55.28 at the start of the year. Since then, ANIP stock has increased by 32.0% and is now trading at $72.95. View the best growth stocks for 2025 here. How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced its quarterly earnings data on Friday, November, 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.09 by $0.25. The firm's revenue was up 12.5% on a year-over-year basis. Read the conference call transcript. Who are ANI Pharmaceuticals' major shareholders? Top institutional shareholders of ANI Pharmaceuticals include Principal Financial Group Inc. (0.72%), Bank of New York Mellon Corp (0.55%), Assenagon Asset Management S.A. (0.53%) and Lisanti Capital Growth LLC (0.48%). Insiders that own company stock include Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Chad Gassert, Stephen P Carey, James G Marken, Christopher Mutz, Meredith Cook, Ori Gutwerg, Krista Davis, Antonio R Pera and Renee P Tannenbaum. View institutional ownership trends. How do I buy shares of ANI Pharmaceuticals? Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ANI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ANI Pharmaceuticals investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings11/08/2024Today5/04/2025Next Earnings (Estimated)5/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CIK1023024 Webwww.anipharmaceuticals.com Phone(218) 634-3500Fax218-634-3540Employees600Year FoundedN/APrice Target and Rating Average Stock Price Target$80.13 High Stock Price Target$94.00 Low Stock Price Target$65.00 Potential Upside/Downside+9.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.14) Trailing P/E RatioN/A Forward P/E Ratio18.90 P/E GrowthN/ANet Income$18.78 million Net Margins-1.28% Pretax Margin-1.35% Return on Equity15.87% Return on Assets6.88% Debt Debt-to-Equity Ratio1.52 Current Ratio2.74 Quick Ratio1.97 Sales & Book Value Annual Sales$614.38 million Price / Sales2.59 Cash Flow$8.08 per share Price / Cash Flow9.03 Book Value$21.13 per share Price / Book3.45Miscellaneous Outstanding Shares21,774,000Free Float18,358,000Market Cap$1.59 billion OptionableOptionable Beta0.49 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:ANIP) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.